当前位置: X-MOL 学术IET Nanobiotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Preparation and characterisation of magnetosomes based drug conjugates for cancer therapy.
IET Nanobiotechnology ( IF 3.8 ) Pub Date : 2020-12-01 , DOI: 10.1049/iet-nbt.2020.0082
Varalakshmi Raguraman 1 , Krishnamurthy Suthindhiran 1
Affiliation  

The authors report a novel, effective and enhanced method of conjugating anticancer drug, paclitaxel and gallic acid with magnetosomes. Here, anticancer drugs were functionalised with magnetosomes membrane by direct and indirect (via crosslinkers: glutaraldehyde and 3-aminopropyltriethoxysilane) adsorption methods. The prepared magnetosome-drug conjugates were characterised by Fourier transform infrared, zeta potential, field-emission scanning electron microscope and thermogravimetric analysis/differential scanning calorimetry. The drug-loading efficiency and capacity were found to be 87.874% for paclitaxel (MP) and 71.3% for gallic acid (MG), respectively as calculated by ultraviolet spectroscopy and high-performance liquid chromatography. The drug release demonstrated by the diffusion method in phosphate buffer (PBS), showing a prolonged drug release for MP and MG, respectively. The cytotoxicity effect of the MP and MG displayed cytotoxicity of 69.71%, 55.194% against HeLa and MCF-7 cell lines, respectively. The reactive oxygen species, acridine orange and ethidium bromide and 4, 6-diamidino-2-phenylindole staining of the drug conjugates revealed the apoptotic effect of MP and MG. Further, the regulation of tumour suppressor protein, p53 was determined by western blotting which showed an upregulation of p53. Comparatively, the magnetosome-drug conjugates prepared by direct adsorption achieved the best effects on the drug-loading efficiency and the increased percentage of cancer cell mortality and the upregulation of P53. The proposed research ascertains that magnetosomes could be used as effective nanocarriers in cancer therapy.

中文翻译:


用于癌症治疗的基于磁小体的药物缀合物的制备和表征。



作者报告了一种将抗癌药物紫杉醇和没食子酸与磁小体结合的新颖、有效和增强的方法。在这里,抗癌药物通过直接和间接(通过交联剂:戊二醛和3-氨基丙基三乙氧基硅烷)吸附方法用磁小体膜功能化。通过傅里叶变换红外、zeta电位、场发射扫描电子显微镜和热重分析/差示扫描量热法对制备的磁小体-药物缀合物进行了表征。通过紫外光谱和高效液相色谱计算,紫杉醇(MP)和没食子酸(MG)的载药效率和容量分别为87.874%和71.3%。通过磷酸盐缓冲液 (PBS) 中的扩散方法证明了药物释放,分别显示 MP 和 MG 的药物释放延长。 MP和MG对HeLa和MCF-7细胞系的细胞毒性分别为69.71%、55.194%。药物缀合物的活性氧、吖啶橙和溴化乙锭以及4,6-二脒基-2-苯基吲哚染色揭示了MP和MG的细胞凋亡作用。此外,通过蛋白质印迹法测定肿瘤抑制蛋白p53的调节,结果显示p53的上调。相比之下,直接吸附制备的磁小体-药物缀合物在载药效率、提高癌细胞死亡率和上调P53方面取得了最佳效果。拟议的研究确定磁小体可以用作癌症治疗中的有效纳米载体。
更新日期:2020-12-01
down
wechat
bug